CMS Delays New Rates for CAR-T

ANCOR is sharing the story below by Politico Pro as an update to this previous story. As CMS develops its interest in adopting new technologies, ANCOR is monitoring to see what precedent this could set for disability supports.

As shared by Politico Pro:

“CMS today said it was delaying release of its final plan for covering CAR-T cell therapies, the nearly half-million dollar cancer treatments like Novartis’ Kymriah and Gilead’s Yescarta. It had been expected today.

‘CMS will not be issuing a final National Coverage Determination on CAR T-cell therapy for cancer today, but a decision is forthcoming,’ the agency said in a brief statement this morning.

Comments on the draft decision, calling for only using CAR-T in hospitals and feeding data to a national registry, wrapped up in March with manufacturers and providers alike warning that the coverage conditions could restrict patient access.”